Come up with a name for your new list and we'll add to it:
Amarin raised a round of funding on , . Investors include
Thomas McNerney & Partners.
Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular disease. The Companys lead product candidate is AMR101, a prescription grade Omega-3 fatty acid comprising not less than…